InsufficientPreprint
This study analyzed a large, publicly available independent testing dataset of 6,441 samples spanning fourteen peptide compounds sold through largely unregulated gray market channels directly to consumers. Compounds examined included BPC-157, semaglutide, tirzepatide, PT-141, TB-500, thymosin beta-4, and others marketed for purposes such as injury recovery, muscle growth, fat loss, and athletic performance. Researchers applied two quality acceptance frameworks — one approximating standards for 503A compounded medications and a stricter model reflecting FDA-approved drug production standards — to assess purity, measured abundance, and endotoxin burden. The study found that between 41.6% and 71.1% of samples failed to meet basic quality criteria depending on the framework applied, and measurable endotoxin contamination was detected in 15% of samples. Gray market peptides were consistently cheaper than FDA-approved alternatives, though cost differentials varied widely (e.g., 72.8% higher for tirzepatide vs. 3,850% higher for PT-141 when comparing FDA-approved options). The authors concluded that consumer-directed third-party testing improves transparency but captures only a fraction of the full safety profile relevant to patients self-administering injectable compounds. Key limitations include reliance on a secondary dataset not collected under controlled research conditions and the inability to assess many other safety dimensions beyond purity and endotoxin levels.
Unknown journal · Apr 2026DOI ↗ 🧪 TrialInsufficient
Registered Phase 2 interventional trial (recruiting). This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.
ClinicalTrials.gov · Feb 2026View trial ↗ Insufficient
This paper is a published correspondence ("Reply") in the journal Pharmaceuticals, in which the original authors of a literature and patent review on the BPC 157 peptide respond to a commentary submitted by Sikiric et al. The reply addresses points raised in the comment regarding BPC 157's proposed mechanisms of action, specifically its purported roles in modulating angiogenesis and nitric oxide (NO) pathways. The responders engage with the argument that BPC 157 may selectively target the cytotoxic and damaging aspects of NO signaling while preserving or restoring its essential protective physiological functions. As a correspondence piece reacting to a comment on a review article, this paper does not present new experimental data, clinical trials, or original preclinical findings. Its contribution is interpretive and editorial in nature, clarifying the scope and conclusions of the original review in light of the mechanistic claims put forth by the commentators. Limitations include the absence of any new empirical evidence; all mechanistic claims discussed are derived from previously published literature cited by both parties.
Pharmaceuticals (Basel, Switzerland) · Sep 2025DOI ↗ Insufficient
This entry corresponds to a withdrawn article originally submitted to the journal Current Neuropharmacology, investigating the use of the stable gastric pentadecapeptide BPC 157 as a potential therapy for severe electrolyte disturbances in rats. The article was retracted at the authors' own request, and the publisher (Bentham Science) provided no details regarding the specific findings, data, or conclusions of the original study. Because the full content of the paper is unavailable — replaced entirely by a withdrawal notice — no experimental methods, results, or conclusions can be evaluated or attributed to the study. The withdrawal notice also includes standard publisher boilerplate regarding submission conditions and plagiarism policy, but does not disclose the reason for withdrawal. As a result, this record cannot be used to draw any conclusions about BPC 157's effects on electrolyte disturbances. Researchers and educators should treat this citation as non-existent in the evidence base, as the underlying data and claims are no longer accessible or endorsed by the authors or publisher.
Current neuropharmacology · Jan 2025DOI ↗ Insufficient
This cross-sectional pilot study examined the direct-to-consumer market for compounded glucagon-like peptide-1 (GLP-1) receptor agonists in Colorado. Researchers conducted Google searches of business websites advertising compounded GLP-1 products for weight loss across census-defined statistical areas between March and April 2024. They identified 93 websites corresponding to 188 physical locations. Most businesses were categorized as medical/health spas or weight loss services. Semaglutide was the most commonly advertised product (92/93 sites), followed by tirzepatide (40/93). Some sites advertised combination formulations including B vitamins, BPC-157 (flagged by the FDA as unsafe for compounding), and other additives. Seven sites advertised oral formulations. Notably, 41 of 93 websites referenced FDA approval in their product descriptions—a potentially misleading claim, as compounded products are not FDA-approved—and 5 sites incorrectly referred to products as "generic." The study's limitations include its focus on a single state, reliance on publicly available website data, and its pilot/cross-sectional design, which limits generalizability. The authors conclude that regulatory action is needed to address misleading advertising and safety concerns in this market.
Journal of pharmaceutical policy and practice · Dec 2024DOI ↗ 🧪 TrialInsufficient
Registered Phase 1 interventional trial (unknown). Phase I clinical trial in healthy volunteers to study safety and pharmacokinetics of BPC-157, a pentadecapeptide from gastric source.
ClinicalTrials.gov · Dec 2015View trial ↗